SCHEMBL1334418

SCHEMBL1334418

CCCn1c(=O)c2c(nc(Cc3ccccc3N)n2CCN(CC)CCO)n(CCc2cccc(N)c2)c1=O

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.54
TSHR P16473 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ADORA2B P29275 3/20 0.37
ADORA2A P29274 2/20 0.37
ADORA3 P0DMS8 5/20 0.37
JAK2 O60674 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1333496 0.93 ADORA1 (0.56) ADORA1TSHRLMNAHTTNPSR1
Hydrochloric Acid SCHEMBL4170259 0.92 ADORA1 (0.55) ADORA1TSHRLMNAHTTNPSR1
SCHEMBL1333475 0.91 ADORA1 (0.58) ADORA1TSHRLMNAHTTNPSR1
SCHEMBL1334380 0.91 ADORA1 (0.53) ADORA1TSHRLMNAHTTNPSR1
SCHEMBL4176173 0.91 ADORA1 (0.62) ADORA1TSHRLMNAHTTNPSR1
SCHEMBL4167641 0.90 ADORA1 (0.52) ADORA1TSHRLMNAHTTNPSR1
SCHEMBL1334260 0.89 ADORA1 (0.56) ADORA1TSHRLMNAHTTNPSR1
Hydrochloric Acid SCHEMBL4174153 0.89 ADORA1 (0.51) ADORA1TSHRLMNAHTTNPSR1
SCHEMBL4182302 0.88 ADORA1 (0.59) ADORA1TSHRLMNAHTTNPSR1
SCHEMBL1333427 0.88 ADORA1 (0.50) ADORA1TSHRLMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902360-B2 e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility WILSON CONSTANCE N 2011-03-08 US claimed
US-20070282105-A1 A1 ADENOSINE RECEPTOR ANTAGONISTS ENDACEA, INC. (US) 2007-12-06 US claimed
US-20050187226-A1 A1 adenosine receptor antagonists ENDACEA, INC. 2005-08-25 US claimed
US-20110282031-A1 A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES WILSON CONSTANCE N (US) 2011-11-17 US disclosed
US-7902360-B2 e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility WILSON CONSTANCE N 2011-03-08 US disclosed
US-20070282105-A1 A1 ADENOSINE RECEPTOR ANTAGONISTS ENDACEA, INC. (US) 2007-12-06 US disclosed
US-7247639-B2 A1 adenosine receptor antagonists ENDACEA, INC. (US) 2007-07-24 US disclosed
US-20050187226-A1 A1 adenosine receptor antagonists ENDACEA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282031-A1 A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES ADORA1, ADORA3, ADORA2A ADORA1 1/4885TSHR 472/4885LMNA 1092/4885
US-20070282105-A1 A1 ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA3, ADORA2A ADORA1 1/4885TSHR 208/4885LMNA 1247/4885
US-20050187226-A1 A1 adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ADORA1 1/4885TSHR 252/4885LMNA 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.